Argenx to Buy Forte Biosciences for $2.2 Billion
A $2.2 billion acquisition agreement marks a significant shift in the immunology market, as Argenx moves to absorb Forte Biosciences.
- Intelligence Anchor: Argenx to Buy Forte Biosciences for $2.2 Billion
- Core Takeaway: A $2.2 billion acquisition agreement marks a significant shift in the immunology market, as Argenx moves to absorb Forte Biosciences.
- Signal Velocity: 8 score across 10 independent media sources and 10 indexed articles.
- Forecast Model: Story projected to maintain momentum over next 24h.
📍 Aftermath
Argenx agreed to acquire Forte Biosciences for $2.2 billion, adding the first-in-class anti-CD122 antibody FB102 to its immunology pipeline. The acquisition included a phase 2-stage vitiligo drug, expanding argenx's presence in the immunology sector. Following the announcement, TD Cowen downgraded Forte Biosciences' stock rating due to the deal.
Epilogue added 97d ago, after coverage quieted.
Sources (10)
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline Yahoo Finance · 99d ago
- Argenx to buy autoimmune-focused Forte Biosciences for $2.2B STAT · 99d ago
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline GlobeNewswire · 99d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal Investing.com · 99d ago
- Argenx to acquire Forte Biosciences for $2.2B Axios · 99d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal By Investing.com Investing.com Canada · 99d ago
- argenx to buy Forte Bio for $2.2B in immunology push FirstWord Pharma · 99d ago
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B Endpoints News · 99d ago
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug Fierce Biotech · 99d ago
- Argenx to Buy Forte Biosciences for $2.2 Billion WSJ · 99d ago
The story so far
The acquisition of Forte Biosciences by Argenx for $2.2 billion is set to reshape the landscape of immunology therapeutics. This transaction involves the transfer of an entire pipeline centered on autoimmune research, most notably the anti-CD122 antibody candidate known as FB102, which is currently in phase 2 trials for conditions such as vitiligo. Argenx initiated this purchase to bolster its specialized portfolio, according to details provided by Yahoo Finance, STAT, and The Wall Street Journal.
The deal effectively brings the clinical-stage asset FB102 under the ownership of Argenx, signaling an effort to consolidate resources within the autoimmune drug sector. Market analysts have already begun to react to the terms of the agreement. Specifically, TD Cowen issued a downgrade on Forte Biosciences stock following the announcement of the acquisition.
While the financial terms of the deal are settled at $2.2 billion, the broader market implications remain the primary point of interest. Regulatory timelines and the finalization of the transition for the research staff and clinical trials are not explicitly detailed in the current coverage.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (89% supported) Updated 97d ago.
The obvious questions
What is the primary asset being acquired?
The acquisition centers on FB102, a first-in-class anti-CD122 antibody currently in phase 2 development for vitiligo.
What was the market reaction to the announcement?
TD Cowen downgraded the stock rating of Forte Biosciences following the news of the deal.
What is the total value of the deal?
The deal is valued at $2.2 billion.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Will this trend continue gaining momentum or fade within 24 hours?
Cast your anonymous vote to register reader sentiment on news cycle velocity.
Topics
Related trends
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
Sanofi’s new CEO Garijo outlines an R&D restructuring and expansion plan as the company balances strong second-quarter earnings against investor concerns.
Exclusive
Reports indicate United Airlines previously sought to merge with Delta and American, signaling a potential shift in major airline consolidation strategy.
Brookfield and CPP Investments to Buy LXP Industrial for $5.2 Billion
Brookfield and CPP Investments have agreed to acquire LXP Industrial Trust in a transaction valued at $5.2 billion.
Netflix Paid $587 Million for Ben Affleck’s AI Startup InterPositive
Netflix has confirmed the acquisition of Ben Affleck’s artificial intelligence startup, InterPositive, for $587 million.
Breakdown of immune cells' interaction is key driver in aging, study finds
New research identifies a breakdown in immune cell interactions as a primary factor in the biological aging process.
Banijay and Mediawan Eye Lionsgate Studios Takeover
Lionsgate Studios shares have surged following reports of potential takeover interest from European media groups.